David Amsellem
Sr. Research Analyst
Research
Sector Expertise
Additional Expertise
Biotechnology
David Amsellem is a managing director and senior research analyst at Piper Sandler covering biotechnology. Amsellem has more than 20 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-2008 and a senior associate on the biotechnology equity research team from 2003-2006. Amsellem earned a Bachelor of Science degree from Cornell University.
Universe Coverage
| Biotechnology | |
|---|---|
| ABBV | AbbVie Inc. |
| ALKS | Alkermes Plc |
| AMGN | Amgen Inc. |
| AMRX | Amneal Pharmaceuticals Inc. |
| AMPH | Amphastar Pharmaceuticals, Inc. |
| ANIP | ANI Pharmaceuticals, Inc. |
| AQST | Aquestive Therapeutics, Inc. |
| AVDL | Avadel Pharmaceuticals plc |
| AXSM | Axsome Therapeutics, Inc. |
| BIIB | Biogen Inc. |
| BMY | Bristol-Myers Squibb Company |
| COLL | Collegium Pharmaceutical, Inc. |
| CORT | Corcept Therapeutics Inc. |
| ESPR | Esperion Therapeutics, Inc. |
| FENC | Fennec Pharmaceuticals, Inc. |
| HRMY | Harmony Biosciences Holdings, Inc. |
| INDV | Indivior PLC |
| JAZZ | Jazz Pharmaceuticals plc |
| NBIX | Neurocrine Biosciences Inc. |
| OGN | Organon & Co. |
| SUPN | Supernus Pharmaceuticals, Inc. |
| TEVA | Teva Pharmaceutical Industries Limited |
| VTRS | Viatris, Inc. |
| XERS | Xeris Pharmaceuticals, Inc. |